SCHEMBL3306513

SCHEMBL3306513

O=S(=O)(c1ccc(Nc2nccc(Nc3ccc(F)c(F)c3)n2)cc1)N1CCC(C(O)c2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 6/20 0.51
CHUK O15111 4/20 0.51
CDK2 P24941 3/20 0.41
CDK4 P11802 1/20 0.41
CCNE1 P24864 1/20 0.41
MAPT P10636 3/20 0.41
AURKA O14965 7/20 0.40
AURKB Q96GD4 4/20 0.40
PIM1 P11309 2/20 0.40
MAP4K4 O95819 1/20 0.40
MAPK8 P45983 1/20 0.40
GSK3B P49841 1/20 0.40
HIPK2 Q9H2X6 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
PLK4 O00444 1/20 0.39
CHEK1 O14757 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3306811 0.93 IKBKB (0.49) IKBKBCHUKCDK2CDK4CCNE1
SCHEMBL13392300 0.93 IKBKB (0.49) IKBKBCHUKCDK2CDK4CCNE1
SCHEMBL13392326 0.87 MAPT (0.50) IKBKBCHUKMAPTMAPK8NPC1
SCHEMBL13392092 0.86 IKBKB (0.44) IKBKBCHUKCDK2CDK4CCNE1
SCHEMBL3295362 0.86 IKBKB (0.44) IKBKBCHUKCDK2CDK4CCNE1
SCHEMBL13392293 0.86 IKBKB (0.42) IKBKBCHUKCDK2CDK4CCNE1
SCHEMBL3300337 0.86 IKBKB (0.42) IKBKBCHUKCDK2CDK4CCNE1
SCHEMBL3300442 0.86 TBK1 (0.49) IKBKBCHUKCDK2CCNE1JAK2
SCHEMBL3301585 0.84 RAB9A (0.47) IKBKBMAPTMAPK8NPC1MAPK1
SCHEMBL13392338 0.84 IKBKB (0.52) IKBKBCHUKCDK2AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
WO-2009056693-A1 NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed
WO-2008099073-A1 N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF SANOFI-AVENTIS (FR) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE IKBKB 2/4885CHUK 1/4885CDK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.